Poland· PL-100404697
Steglujan
A sitagliptin and ertugliflozin product containing ertugliflozinum + sitagliptinum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sitagliptin and ertugliflozin is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD24 (sitagliptin and ertugliflozin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Sitagliptin and ertugliflozin · ATC A10BD24
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Ertugliflozinum + Sitagliptinum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- A10BD24
- ATC class
- Sitagliptin and ertugliflozin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin00191778018578
- gtin00191778018585
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sitagliptin and ertugliflozin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSTEGLUJANMerck Sharp & Dohme B.V., Haarlem
- SwitzerlandSteglujan 5 mg /100 mg, FilmtablettenMSD Merck Sharp & Dohme AG
- IcelandSteglujanMerck Sharp & Dohme B.V.*
- SwedenSteglujan 15 mg/100 mg Filmdragerad tablettMerck Sharp & Dohme BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Steglujan
- Liechtenstein · Steglujan
- Norway · Steglujan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c94a88c5-ca2d-48d2-9e74-bce06bc24268 GET /v1/drugs/c94a88c5-ca2d-48d2-9e74-bce06bc24268?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "5 mg + 100 mg",
"packaging": "00191778018578 ¦ Rp ¦ EU/1/18/1266 /001 ¦ 127803\n14 tabl.\n00191778018585 ¦ Rp ¦ EU/1/18/1266 /002 ¦ 127804\n28 tabl.\nRp ¦ EU/1/18/1266 /003 ¦ 127805\n30 tabl.\nRp ¦ EU/1/18/1266 /004 ¦ 127806\n30 tabl. (1 x 30)\nRp ¦ EU/1/18/1266 /006 ¦ 127807\n90 tabl.\nRp ¦ EU/1/18/1266/013 ¦ 131665\n98 tabl.\nRp ¦ EU/1/18/1266/005 ¦ 160140\n84 tabl.",
"substance": "Ertugliflozinum 5 mg + Sitagliptinum 100 mg",
"common_name": "Ertugliflozinum + Sitagliptinum",
"pl_product_id": "100404697",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sitagliptin and ertugliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.